May 21, 2018 09:58 AM EDT

GSK gets European OK for HIV drug Juluca; Akari dealt non-compliance notice from Nasdaq

Amber Tong

→ GSK’s ViiV has snared a European approval for Juluca, which the pharma giant touts as the first 2-drug, once-daily, single pill regimen OK’d for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK gets European OK for HIV drug Juluca; Akari dealt non-compliance notice from Nasdaq

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

GSK gets Eu­ro­pean OK for HIV drug Ju­lu­ca; Akari dealt non-com­pli­ance no­tice from Nas­daq

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

GSK gets European OK for HIV drug Juluca; Akari dealt non-compliance notice from Nasdaq

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial